- Home
- TMP vs OPT Comparison
TMP vs OPT Comparison
Compare TMP & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMP
- OPT
- Stock Information
- Founded
- TMP 1836
- OPT 1984
- Country
- TMP United States
- OPT Australia
- Employees
- TMP N/A
- OPT N/A
- Industry
- TMP Major Banks
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TMP Finance
- OPT Health Care
- Exchange
- TMP Nasdaq
- OPT Nasdaq
- Market Cap
- TMP 892.4M
- OPT 767.9M
- IPO Year
- TMP N/A
- OPT 2020
- Fundamental
- Price
- TMP $75.40
- OPT $3.24
- Analyst Decision
- TMP Buy
- OPT Strong Buy
- Analyst Count
- TMP 1
- OPT 1
- Target Price
- TMP $68.00
- OPT $12.00
- AVG Volume (30 Days)
- TMP 61.7K
- OPT 39.0K
- Earning Date
- TMP 10-25-2024
- OPT 08-30-2024
- Dividend Yield
- TMP 3.29%
- OPT N/A
- EPS Growth
- TMP 376.41
- OPT N/A
- EPS
- TMP 4.64
- OPT N/A
- Revenue
- TMP $286,367,000.00
- OPT $261,859.00
- Revenue This Year
- TMP N/A
- OPT N/A
- Revenue Next Year
- TMP $6.80
- OPT $46,864.64
- P/E Ratio
- TMP $16.24
- OPT N/A
- Revenue Growth
- TMP 30.04
- OPT N/A
- 52 Week Low
- TMP $43.09
- OPT $1.79
- 52 Week High
- TMP $78.28
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- TMP 65.43
- OPT 27.29
- Support Level
- TMP $73.52
- OPT $4.02
- Resistance Level
- TMP $76.68
- OPT $4.18
- Average True Range (ATR)
- TMP 2.71
- OPT 0.22
- MACD
- TMP 0.56
- OPT -0.13
- Stochastic Oscillator
- TMP 80.76
- OPT 6.85
About TMP Tompkins Financial Corporation
Tompkins Financial Corp is a Financial Holding Company. It has three business segments, consisting of banking, insurance and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Insurance is comprised of property and casualty insurance services and employee benefit consulting. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates majority of its revenue from Banking segment.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.